Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Richard E. Pratley(Translational Research Institute for Metabolism and Diabetes), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Olav Wendelboe Nielsen(University of Copenhagen), Richard J. MacIsaac, Samy Hadjadj(Université de Poitiers), Johannes F.E. Mann(Katholische Stiftungshochschule München), Katherine R. Tuttle(Providence Regional Medical Center Everett), Mikhail Kosiborod(AstraZeneca (Brazil)), Zdravko Kamenov(Medical University of Sofia), Marco Bo Hansen(University of Copenhagen), Peter Rossing(Steno Diabetes Centers), Vlado Perkovic(University of Copenhagen), Florian M.M. Baeres(University of Copenhagen), George L. Bakris(Pennsylvania State System of Higher Education), Thomas Idorn(University of Copenhagen), Søren Rasmussen(Novo Nordisk (Denmark))
Cited by 107
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k